Tweetovi

Blokirali ste korisnika/cu @ValiantVarriors

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ValiantVarriors

  1. 29. sij

    To answer many recent queries about impact of the current virus: based on our checks, Vitasoy's Wuhan plant makes up 20-25% of total manufacturing capacity (including sales to HK entity)...

    Poništi
  2. 21. sij

    Our reply to Vitasoy's clarification. Company is using inter-company transactions to fabricate China profits?

    Poništi
  3. 17. sij
    Poništi
  4. 16. sij
    Prikaži ovu nit
    Poništi
  5. 16. sij

    We are SHORT VITASOY HK 0345 Overstated profits and capex, oversold China story

    Prikaži ovu nit
    Poništi
  6. 15. sij

    Tomorrow we will be releasing our first short report for 2020. Stay tuned.

    Poništi
  7. proslijedio/la je Tweet

    It’s official: Bio-on has been officially declared bankrupt by the Italian authorities. Bio-OFF

    Poništi
  8. proslijedio/la je Tweet

    Good morning London! MW is short NMC Health We have serious doubts about the company’s financial statements, including its asset values, cash balance, reported profits, and reported debt levels.

    Poništi
  9. 26. stu 2019.

    HLB blatantly lied about the "Best of ESMO 2019" award! What else are they hiding??

    Poništi
  10. 16. stu 2019.

    So we're referred to as "fake news" and "fake report" by HLB. If HLB is so confident, we'd like to invite them to answer our 6 questions and disclose their FDA meeting minutes

    Poništi
  11. 11. stu 2019.
    Prikaži ovu nit
    Poništi
  12. 11. stu 2019.
    Prikaži ovu nit
    Poništi
  13. 11. stu 2019.

    Based on the results of just the third-line patients, the drug arm killed faster than placebo.

    Prikaži ovu nit
    Poništi
  14. 11. stu 2019.

    Its safety record is also exceedingly poor. More than a quarter of the patients in the Phase III trial dropped out, while 47.6 per cent of them – an unusually high number –experienced serious side effects.

    Prikaži ovu nit
    Poništi
  15. 11. stu 2019.

    The drug Rivoceranib, targeted to be used as a third-line gastric cancer treatment, is not only less effective than existing drugs on the market, it also poses more safety hazards.

    Prikaži ovu nit
    Poništi
  16. 11. stu 2019.

    HLB 028300 Buyers beware! A sham company looking to swindle its investors. Run while you still can!

    Prikaži ovu nit
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·